BioSpace News Archive

Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track with topline data expected in late 2019

Triple-S Management Corporation, a leading managed care company in Puerto Rico, announced its third quarter 2019 results.

Investment to support development of human-compatible xeno organs to address the global organ shortage crisis

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation devices, announced that it will release financial results for the third quarter and first nine months of 2019, and provide an update on U.S.

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced that Brian J. Brille, Vice Chairman of the Company, will present at two upcoming investor healthcare conferences in New York City.

New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting

TransThera Biosciences Co. Ltd, announced that company received Orphan Drug Designation from US Food and Drug Administration for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, will present its latest patient treatment data and key findings at the 15th Annual Neuroscience Education Insitute (NEI) Congress in Colorado, November 7-10, 2019.

Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced the completion of enrollment and dosing in its Phase 1 trial of INXN-4001, a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure, the leading cause of death worldwide.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2020 operating results on Wednesday, November 13, 2019 before the open of the U.S. financial markets.